✦ LIBER ✦

Characterization of the invasive and metastatic phenotype in human renal cell carcinoma

✍ Scribed by Ikuo Saiki; Seiji Naito; Junya Yoneda; Ichiro Azuma; Janet E. Price; Isaiah J. Fidler

Book ID: 105304309
Publisher: Springer
Year: 1991
Tongue: English
Weight: 996 KB
Volume: 9
Category: Article
ISSN: 0262-0898
DOI: 10.1007/bf01768583

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Capecitabine in the treatment of metasta

Capecitabine in the treatment of metastatic renal cell carcinoma

✍ Oevermann, K; Buer, J; Hoffmann, R; Franzke, A; Schrader, A; Patzelt, T; Kirchne 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 192 KB

Combination of surgery and immunotherapy

Combination of surgery and immunotherapy in metastatic renal cell carcinoma

✍ Gerald H. Mickisch; Roland H. Mattes 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 187 KB

Novel approaches in the therapy of metas

Novel approaches in the therapy of metastatic renal cell carcinoma

✍ John S. Lam; John T. Leppert; Arie S. Belldegrun; Robert A. Figlin 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 434 KB

In vivoselection of human renal cell car

In vivoselection of human renal cell carcinoma cells with high metastatic potential in nude mice

✍ Seiji Naito; Shirley M. Walker; Isaiah J. Fidler 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 513 KB

In vitro modulation of the invasive and

In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer

✍ Robert W. Hathorn; Cho-Lea Tso; Randhir Kaboo; Shen Pang; Robert Figlin; Charles 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 899 KB

Reverse transcriptase inhibitors induce

Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma

✍ Matteo Landriscina; Settimia Anna Altamura; Leonarda Roca; Margherita Gigante; A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 427 KB

## Abstract Reverse transcriptase (RT) inhibitors are emerging as a novel class of anticancer differentiating agents, active in several human tumor cell models, such as melanoma and prostate, thyroid and colon carcinoma. Indeed, much evidence suggests that they may act by inhibiting endogenous RT,